DEA greenlights increased production, importation of controlled substances amid COVID-19 shortages

Apr 07, 2020 - 04:15 PM

The Drug Enforcement Agency today said it is increasing annual caps for controlled substances whose supplies are in high demand due the COVID-19 crisis. DEA said it will increase the 2020 Aggregate Production Quotas by 15% for certain substances needed for the treatment of COVID-19, including fentanyl, morphine, hydromorphone, codeine, ephedrine, pseudoephedrine, and certain controlled substance intermediates which are essential to their production. The agency also is increasing the authorized amounts of certain schedule III and IV controlled substances needed to treat patients on ventilators that may be imported into the United States, including ketamine, diazepam, midazolam, lorazepam, and phenobarbital.

DEA said it will reevaluate demand and adjust APQ levels as needed after the health emergency recedes.

In a letter sent April 1, the AHA, American Medical Association, American Society of Anesthesiologists, American Society of Health-System Pharmacists, and Association for Clinical Oncology urged DEA to allow drug manufacturers and 503B outsourcing facilities to receive increased APQ controlled-substance allocations during the COVID-19 crisis.

Related News Articles

Headline
Recall issued for mislabeled potassium chloride
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
Study finds flu, COVID-19 infection temporarily raises risk of heart attack, stroke 
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
CDC adopts ACIP recommendations for COVID-19, chickenpox vaccines
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
FDA seeks feedback on measuring AI-enabled medical device performance
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
Olympus recalls endoscope needles
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
ACIP recommends patients consult their provider for COVID-19 vaccine
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…